Carprazidil | CAS#68020-77-9 | vasoactive antihypertensive

MedKoo Cat#: 412392 | Name: Carprazidil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carprazidil is a vasoactive antihypertensive agent which does not produce tachycardia or water & sodium retention.

Chemical Structure

Carprazidil

CAS#68020-77-9

Theoretical Analysis

MedKoo Cat#: 412392

Name: Carprazidil

CAS#: 68020-77-9

Chemical Formula: C12H13N5O4

Exact Mass: 291.0968

Molecular Weight: 291.27

Elemental Analysis: C, 49.48; H, 4.50; N, 24.04; O, 21.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Carprazidil; Carprazidilum; UNII-O55EMK06L9

IUPAC/Chemical Name

Carbamic acid, (5-(3,6-dihydro-1(2H)-pyridinyl)-2-oxo-2H-(1,2,4)oxadiazolo(2,3-a)pyrimidin-7-yl)-, methyl ester

InChi Key

LIQCCUFOYBAGQT-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H13N5O4/c1-20-11(18)14-9-7-8(16-5-3-2-4-6-16)13-10-15-12(19)21-17(9)10/h2-3,7H,4-6H2,1H3,(H,14,18)

SMILES Code

O=C(OC)NC(N1O2)=CC(N3CC=CCC3)=NC1=NC2=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 291.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bianchetti MG, Weidmann P, Boehringer K, Link L, Schiffl H, Beretta-Piccoli C, Colombo JP. Comparative evaluation of the new vasodilator carprazidil and minoxidil in the treatment of moderate to severe hypertension. Eur J Clin Pharmacol. 1982;23(6):483-9. doi: 10.1007/BF00637493. PMID: 7160416. 2: Gerber A, Weidmann P, Saner R, Bianchetti M, Zbinden R, Link L, Riesen W, Mordasini R. Increased serum high-density lipoprotein cholesterol in hypertensive men treated with the potent vasodilator carprazidil. Metabolism. 1984 Apr;33(4):342-6. doi: 10.1016/0026-0495(84)90196-3. PMID: 6708817. 3: Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs. 1988;35 Suppl 6:118-34. doi: 10.2165/00003495-198800356-00017. PMID: 3042351. 4: Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension. 1983 Sep-Oct;5(5 Pt 2):III120-31. doi: 10.1161/01.hyp.5.5_pt_2.iii120. PMID: 6138309. 5: Glueck CJ. Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am Heart J. 1985 Nov;110(5):1107-15. doi: 10.1016/0002-8703(85)90225-x. PMID: 2865887. 6: Gerold M, Eigenmann R, Hefti F, Daum A, Haeusler G. Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713. J Pharmacol Exp Ther. 1981 Mar;216(3):624-33. PMID: 7009831. 7: Cocco G, Strozzi C, Padula A, Al Yassini K, Bulgarelli R, Sfrisi C, Zaniol P. Vasodilator treatment for mild to moderate heart failure. Effect of Ro 12-4713, a minoxidil analogue. Cardiology. 1984;71(4):184-9. doi: 10.1159/000173663. PMID: 6478464. 8: Strozzi C, Cocco G, Tasini MT, Padula A, Rizzo A, Alfiero R, Urso L, Montanari L, Portaluppi F. Effetti della nifedipina e di un vasodilatatore arterioso minoxidil-simile sull'ischemia miocardica al controllo elettrocardiografico dinamico [Effects of nifedipine and a minoxidil-like arterial vasodilator on myocardial ischemia under dynamic electrocardiographic monitoring]. Clin Ter. 1986 Jul 15;118(1):9-12. Italian. PMID: 3742977. 9: Grimm M, Weidmann P, Meier A, Ziegler WH, Reubi FC. Acute effects of a new vasodilator, Ro 12-4713, on blood pressure, plasma Renin activity, Aldosterone and Catecholamine levels, and renal function in hypertensive and normal subjects. Eur J Clin Pharmacol. 1981;20(3):169-77. doi: 10.1007/BF00544594. PMID: 7026257. 10: Chu D, Cocco G, Strozzi C, Vallini R, Nonato M, Amrein R. Antihypertensive effects of a novel peripheral vasodilator, Ro 12-4713. Eur J Clin Pharmacol. 1981 Mar;19(4):233-8. doi: 10.1007/BF00562798. PMID: 7286027.